Disease · MONDO_0023557

infective vaginitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. infective vaginitis. Diseases, record MONDO_0023557. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0023557

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: infective vaginitis; Open Targets
Open Targets ID: MONDO_0023557; Open Targets
Other names: vaginal infection; Open Targets
NCI Thesaurus: C84353; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUTOCONAZOLE NITRATE	CHEMBL1200398	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CLINDAMYCIN PHOSPHATE	CHEMBL3184512	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TERCONAZOLE	CHEMBL1714574	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TIMBETASIN ACETATE	CHEMBL4594314	Protein	Phase 2	TTD	1	0	0	Drugs and targets
BIFIDOBACTERIUM SPP.	CHEMBL4297912		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02308007	Multi-Center Study of New Medications to Treat Vaginal Infections	Phase 3	475	2020-08-04	Vaginal Infection	METRONIDAZOLE, TERCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02308046	Multi-Center Study of New Medications to Treat Vaginal Infections	Phase 3	212	2020-07-27	Vaginal Infection	TERCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02308033	Multi-Center Study of New Medications to Treat Vaginal Infections	Phase 3	204	2020-07-27	Vaginal Infection	METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00616330	Vaginal Infection Study	Phase 3	1,443		Vulvovaginitis, Vaginitis	BUTOCONAZOLE NITRATE, CLINDAMYCIN PHOSPHATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00694928	Vaginal Infection Study 2	Phase 3	843		Vaginal Infection	BUTOCONAZOLE NITRATE, CLINDAMYCIN PHOSPHATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Terconazole Vaginal Gel vs Gel Vehicle: Number of Participants With Treatment Emergent Adverse Events	39 of 102	38 of 99	201	NCT02308046	Trial comparisons
Terconazole Vaginal Gel vs Gel Vehicle: deaths from any cause	0 of 102	0 of 99	201	NCT02308046	Trial comparisons
Terconazole Vaginal Gel vs Gel Vehicle: serious adverse events	0 of 102	0 of 99	201	NCT02308046	Trial comparisons
Metronidazole Vaginal Gel vs Gel Vehicle: Number of Participants With Treatment Emergent Adverse Events	42 of 96	31 of 97	193	NCT02308033	Trial comparisons
Metronidazole Vaginal Gel vs Gel Vehicle: deaths from any cause	0 of 96	0 of 97	193	NCT02308033	Trial comparisons
Metronidazole Vaginal Gel vs Gel Vehicle: serious adverse events	0 of 96	0 of 97	193	NCT02308033	Trial comparisons
Metronidazole Vaginal Gel vs Gel Vehicle: Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit	43 of 76	32 of 83	159	NCT02308033	Trial comparisons
Metronidazole Vaginal Gel vs Gel Vehicle: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit	47 of 76	18 of 83	159	NCT02308033	Trial comparisons
Terconazole Vaginal Gel vs Gel Vehicle: Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit	45 of 73	29 of 67	140	NCT02308046	Trial comparisons
Terconazole Vaginal Gel vs Gel Vehicle: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit	47 of 73	25 of 67	140	NCT02308046	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0023557

GET https://conductscience.org/api/diseases/v1/MONDO_0023557/drugs

API reference For AI assistants